• ML385 in Redox and Ferroptosis Research: Beyond Cancer Model

  2026-05-20

  Explore how ML385, a selective NRF2 inhibitor, enables advanced study of ferroptosis, oxidative stress, and therapeutic resistance across disease models. Discover unique mechanistic insights and practical assay guidance grounded in recent translational findings.

• Rotigotine: Mechanistic Innovation for Next-Gen PD Research

  2026-05-20

  A comprehensive, evidence-driven examination of rotigotine as a dopamine D2/D3 receptor agonist, integrating mechanistic insight, translational guidance, and strategic workflow advice for researchers advancing Parkinson’s disease models and neuroprotection studies.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Precision in Proteasome Inhib

  2026-05-19

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) brings unmatched control to proteasome inhibition assays, enabling highly reproducible apoptosis and cell cycle arrest research. With reversible, nanomolar potency and robust cell permeability, it stands apart for dissecting protein degradation mechanisms in complex models.

• MG-132 (Z-LLL-al): Benchmarks for Proteasome Inhibition Rese

  2026-05-19

  MG-132 (Z-LLL-al) is a potent, cell-permeable peptide aldehyde proteasome inhibitor that selectively targets the ubiquitin-proteasome system in eukaryotic cells. It induces apoptosis, cell cycle arrest, and oxidative stress, with validated applications in cancer research and mechanistic studies of protein homeostasis. This article provides evidence-backed benchmarks, protocol guidance, and clarifies common misconceptions for MG-132 experimental use.

• Adipose-Neural Axis in Cardiac Arrhythmias: Mechanistic Insi

  2026-05-18

  This article reviews Fan et al.'s mechanistic study showing how adipocyte-derived leptin activates sympathetic neurons to trigger cardiac arrhythmias via neuropeptide Y (NPY) signaling and downstream targets. Their coculture model provides new experimental and therapeutic perspectives for understanding epicardial adipose tissue's role in arrhythmogenesis.

• CD44-Mediated Metabolic Rewiring in IDH-Mutant AML: A Target

  2026-05-18

  This study uncovers how CD44 upregulation in IDH-mutant leukemia rewires cellular metabolism to sustain pathological 2-hydroxyglutarate (R-2HG) production, revealing a critical metabolic dependency. Targeting the CD44-driven pathway presents a promising therapeutic vulnerability, with direct implications for refining strategies in acute myeloid leukemia research.

• ML-7 Hydrochloride: Mechanistic Foundations and Next-Gen Ass

  2026-05-17

  Explore the mechanistic foundations of ML-7 hydrochloride as a myosin light chain kinase inhibitor, with deep analysis of its implications for advanced cardiovascular and endothelial research. This article uniquely connects molecular action to practical assay strategy.

• Carboxylesterase Interference in Amplex Red Mitochondrial H2

  2026-05-16

  Miwa et al. (2016) revealed that carboxylesterases can directly convert Amplex Red to resorufin, independent of H2O2, challenging the specificity of a widely used mitochondrial hydrogen peroxide assay. Their findings highlight the need for methodological refinement in reactive oxygen species measurement, with critical implications for the interpretation of oxidative stress data in basic and translational research.

• MG-132 in Cancer Research: Protocols, Precision, and Insight

  2026-05-15

  MG-132 (Z-LLL-al) stands at the forefront of proteasome inhibition, empowering apoptosis assays and cell cycle arrest studies with unparalleled specificity. This guide delivers data-driven workflows, troubleshooting strategies, and translational context for maximizing reproducibility and sensitivity in cancer research.

• Exo1: Precision Membrane Trafficking Inhibition in Exocytosi

  2026-05-15

  Exo1 (methyl 2-(4-fluorobenzamido)benzoate) enables acute, mechanism-distinct inhibition of Golgi-to-ER trafficking, empowering advanced exocytic pathway research and high-fidelity exocytosis assays. Its selectivity for ARF1 release—without disrupting the trans-Golgi network—offers unique experimental control and interpretability in tumor extracellular vesicle studies.

• KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyros

  2026-05-14

  KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine delivers selective, high-potency CaMKII inhibition, enabling rigorous dissection of calcium signaling, insulin regulation, and cell cycle control. This guide translates bench-validated workflows and expert troubleshooting into actionable lab protocols, leveraging APExBIO’s trusted formulation for reproducible results.

• ACSF3 Variant Drives Human Height and Metabolic Rate Evoluti

  2026-05-14

  Zhang et al. identify a regulatory variant (rs34590044-A) that upregulates ACSF3, simultaneously increasing human height and basal metabolic rate (BMR). This study reveals how metabolic homeostasis links genetic adaptation, dietary shifts, and key human phenotypes, with direct implications for metabolic and evolutionary biology.

• Isradipine (Dynacirc) in Neuroprotection & Vascular Research

  2026-05-13

  Isradipine (Dynacirc) from APExBIO stands out as a high-purity, research-grade L-type calcium channel blocker, enabling precise interrogation of calcium-mediated processes in neurodegeneration and vascular smooth muscle function. This guide delivers actionable protocols, troubleshooting insights, and comparative context for scientists deploying isradipine in cutting-edge excitotoxicity and hypertension research.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling

  2026-05-13

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) unlocks precise control over calcium homeostasis via selective SERCA inhibition, enabling advanced studies in hematopoietic stem cell mobilization and calcium signaling. This article delivers protocol enhancements, troubleshooting insight, and applied strategies for maximizing the translational impact of BHQ in both basic and preclinical workflows.

• ML133 HCl: Precision Tool for Decoding Kir2.1 Channel Functi

  2026-05-12

  Explore how ML133 HCl, a selective potassium channel inhibitor, revolutionizes pulmonary artery smooth muscle cell proliferation research. This article unveils advanced assay strategies and practical insights unavailable elsewhere.

14727 records 1/982 page Next 12345 下5页 Last page